CAM
RGNX icon

Cresset Asset Management’s Regenxbio RGNX Stock Holding History

Cresset Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,731
Closed -$374K – 2162
2024
Q1 		$374K Buy
17,731
+306
+2% +$5.45K ﹤0.01% 1477
2023
Q4 		$313K Buy
17,425
+75
+0.4% +$1.32K ﹤0.01% 1471
2023
Q3 		$286K Buy
17,350
+80
+0.5% +$1.45K ﹤0.01% 1454
2023
Q2 		$345K Buy
+17,270
New +$333K ﹤0.01% 1461
2022
Q1 		– Sell
-10,847
Closed -$354K – 1116
2021
Q4 		$354K Buy
+10,847
New +$369K ﹤0.01% 818
2019
Q2 		– Sell
-61
Closed -$3K – 1412
2019
Q1 		$3K Buy
+61
New +$3.02K ﹤0.01% 1538

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Cresset Asset Management's RGNX Position: Q2 2024 in Review

Cresset Asset Management sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 17,731 shares — an estimated $374K sold.

Cresset Asset Management first reported a position in RGNX in Q1 2019 and held it in 6 quarters. The position peaked at $374K in Q1 2024. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

  • Cresset Asset Management reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
  • Cresset Asset Management sold 17,731 Regenxbio shares in Q2 2024, an estimated $374K.
  • Cresset Asset Management first reported a position in Regenxbio in Q1 2019 and held it in 6 quarters.
  • Cresset Asset Management's Regenxbio position peaked at $374K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Cresset Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.